Cipla Ltd
Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157)
- Market Cap ₹ 1,16,886 Cr.
- Current Price ₹ 1,447
- High / Low ₹ 1,702 / 1,192
- Stock P/E 25.4
- Book Value ₹ 351
- Dividend Yield 0.90 %
- ROCE 22.8 %
- ROE 16.8 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 25.1% CAGR over last 5 years
- Company has been maintaining a healthy dividend payout of 22.0%
Cons
- The company has delivered a poor sales growth of 9.51% over past five years.
- Promoter holding has decreased over last 3 years: -5.20%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Part of Nifty LargeMidcap 250 Nifty Growth Sectors 15 Nifty Total Market BSE LargeCap BSE 100 ESG Index (INR)
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
8,279 | 10,173 | 11,345 | 13,790 | 14,394 | 15,156 | 16,362 | 17,132 | 19,160 | 21,763 | 22,753 | 25,774 | 26,512 | |
6,065 | 8,026 | 9,183 | 11,310 | 11,898 | 12,329 | 13,265 | 13,926 | 14,907 | 17,211 | 17,726 | 19,483 | 19,847 | |
Operating Profit | 2,214 | 2,147 | 2,163 | 2,480 | 2,496 | 2,826 | 3,097 | 3,206 | 4,252 | 4,553 | 5,027 | 6,291 | 6,665 |
OPM % | 27% | 21% | 19% | 18% | 17% | 19% | 19% | 19% | 22% | 21% | 22% | 24% | 25% |
245 | 251 | 164 | 208 | 208 | 280 | 477 | 344 | 266 | 99 | 293 | 552 | 590 | |
Interest | 34 | 146 | 168 | 207 | 159 | 114 | 168 | 197 | 161 | 106 | 110 | 90 | 81 |
Depreciation | 330 | 373 | 505 | 754 | 1,323 | 1,323 | 1,326 | 1,175 | 1,068 | 1,052 | 1,172 | 1,051 | 1,040 |
Profit before tax | 2,095 | 1,880 | 1,654 | 1,727 | 1,222 | 1,669 | 2,079 | 2,178 | 3,290 | 3,493 | 4,038 | 5,702 | 6,133 |
Tax % | 26% | 25% | 24% | 19% | 15% | 15% | 27% | 29% | 27% | 27% | 30% | 27% | |
1,545 | 1,404 | 1,229 | 1,383 | 1,035 | 1,417 | 1,492 | 1,500 | 2,389 | 2,547 | 2,833 | 4,154 | 4,481 | |
EPS in Rs | 19.24 | 17.29 | 14.71 | 16.93 | 12.51 | 17.52 | 18.96 | 19.18 | 29.82 | 31.19 | 34.71 | 51.05 | 55.42 |
Dividend Payout % | 10% | 12% | 14% | 12% | 16% | 17% | 16% | 21% | 17% | 16% | 24% | 25% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 10% |
3 Years: | 10% |
TTM: | 8% |
Compounded Profit Growth | |
---|---|
10 Years: | 12% |
5 Years: | 25% |
3 Years: | 21% |
TTM: | 30% |
Stock Price CAGR | |
---|---|
10 Years: | 9% |
5 Years: | 26% |
3 Years: | 17% |
1 Year: | 20% |
Return on Equity | |
---|---|
10 Years: | 12% |
5 Years: | 14% |
3 Years: | 14% |
Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 161 | 162 |
Reserves | 8,858 | 9,890 | 10,641 | 11,356 | 12,383 | 14,068 | 14,851 | 15,602 | 18,165 | 20,680 | 23,246 | 26,545 | 28,201 |
967 | 1,248 | 1,703 | 5,202 | 4,113 | 4,098 | 4,316 | 2,816 | 2,014 | 1,056 | 803 | 559 | 461 | |
1,672 | 2,102 | 3,166 | 4,331 | 4,213 | 4,346 | 4,433 | 4,843 | 4,514 | 4,960 | 5,089 | 5,267 | 5,832 | |
Total Liabilities | 11,658 | 13,400 | 15,670 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,300 | 32,533 | 34,655 |
3,610 | 6,496 | 6,830 | 9,368 | 9,492 | 9,950 | 9,608 | 9,683 | 9,516 | 9,683 | 9,160 | 9,607 | 10,342 | |
CWIP | 378 | 442 | 581 | 2,061 | 1,683 | 981 | 676 | 825 | 969 | 766 | 1,093 | 1,153 | 1,097 |
Investments | 2,532 | 709 | 640 | 759 | 973 | 1,259 | 2,554 | 1,471 | 2,710 | 2,551 | 3,662 | 5,449 | 4,995 |
5,138 | 5,753 | 7,620 | 8,862 | 8,721 | 10,483 | 10,923 | 11,444 | 11,661 | 13,857 | 15,384 | 16,323 | 18,221 | |
Total Assets | 11,658 | 13,400 | 15,670 | 21,049 | 20,869 | 22,673 | 23,762 | 23,423 | 24,855 | 26,857 | 29,300 | 32,533 | 34,655 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
1,398 | 1,563 | 1,173 | 1,741 | 2,382 | 1,463 | 1,691 | 3,068 | 3,755 | 3,326 | 3,238 | 4,134 | |
-2,063 | -1,265 | -950 | -4,533 | -1,304 | -834 | -1,688 | 114 | -2,374 | -1,858 | -2,376 | -2,982 | |
718 | -266 | 165 | 3,104 | -1,326 | -385 | -349 | -2,949 | -1,240 | -1,600 | -958 | -1,200 | |
Net Cash Flow | 53 | 33 | 388 | 312 | -248 | 243 | -345 | 234 | 141 | -132 | -97 | -49 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 74 | 59 | 64 | 62 | 65 | 75 | 93 | 83 | 66 | 57 | 65 | 68 |
Inventory Days | 295 | 273 | 329 | 273 | 239 | 271 | 250 | 267 | 232 | 230 | 228 | 217 |
Days Payable | 102 | 92 | 126 | 106 | 108 | 142 | 123 | 139 | 103 | 108 | 112 | 102 |
Cash Conversion Cycle | 266 | 239 | 267 | 230 | 196 | 204 | 220 | 211 | 195 | 180 | 181 | 182 |
Working Capital Days | 142 | 126 | 133 | 121 | 111 | 129 | 143 | 122 | 106 | 103 | 122 | 125 |
ROCE % | 24% | 19% | 15% | 13% | 7% | 9% | 11% | 12% | 17% | 17% | 18% | 23% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
5 Dec - The Operations and Administrative Committee of the Company on 5th December, 2024 has allotted 1,532 fully paid-up equity shares of INR 2 each, pursuant to …
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
2 Dec - Cipla faces INR 10.95 Cr GST penalty; plans to appeal.
-
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
2 Dec - Disclosure of substantial share sale by promoters.
-
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (LODR) Regulations, 2015
30 Nov - Cipla receives ESG Score of 70.2 from SES.
-
Intimation Under Regulation 30 Of SEBI (LODR) Regulations, 2015
28 Nov - Cipla Ltd. discloses GST penalty of INR 53,09,449.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Jul 2024Transcript PPT
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Jan 2024TranscriptNotesPPT
-
Oct 2023Transcript PPT
-
Aug 2023TranscriptPPT
-
Jul 2023Transcript PPT
-
Jul 2023TranscriptNotesPPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
Jul 2022TranscriptNotesPPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Aug 2021Transcript PPT
-
Jun 2021TranscriptPPT
-
May 2021TranscriptPPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptPPT
-
Feb 2021Transcript PPT
-
Jan 2021Transcript PPT
-
Nov 2020TranscriptPPT
-
Nov 2020Transcript PPT
-
Aug 2020TranscriptPPT
-
Aug 2020Transcript PPT
-
May 2020TranscriptPPT
-
May 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Feb 2020Transcript PPT
-
Nov 2019TranscriptPPT
-
Nov 2019Transcript PPT
-
Aug 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
Jun 2019TranscriptPPT
-
May 2019Transcript PPT
-
May 2019TranscriptNotesPPT
-
Feb 2019TranscriptPPT
-
Feb 2019Transcript PPT
-
Nov 2018TranscriptPPT
-
Nov 2018Transcript PPT
-
Aug 2018Transcript PPT
-
May 2018TranscriptNotesPPT
-
Feb 2018Transcript PPT
-
Feb 2018TranscriptNotesPPT
-
Nov 2017TranscriptNotesPPT
-
Aug 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
May 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Nov 2016TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
-
May 2016TranscriptNotesPPT
-
Nov 2015TranscriptNotesPPT
-
Aug 2015TranscriptNotesPPT
Market Leadership[1]
# 3rd largest in the India domestic Rx market
# Leadership in Gx
# 1st rank in Respiratory
# Top 5 in Urology and Anti-infectives.
# Over 5 Lac+ no of downloads - Digital Breathe free
# 7,500+ field force detailing to HCPs across the country – 85% of physicians prescribe at least one Cipla product.
# 3rd largest player in private Rx market in SAGA
# Fastest growing generic player in North America.